GE HealthCare Technologies Inc. · Healthcare · Health Information Services
Scores & Status Key
AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
Last
$69.58
−$0.77 (−1.10%) 3:59 PM ET
After hours$69.50
−$0.08 (−0.11%) 11:44 PM ET
Prev closePrevC$70.35
OpenOpen$71.00
Day highHigh$71.35
Day lowLow$69.47
VolumeVol2,193,714
Avg volAvgVol3,749,871
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
Mkt cap
$31.78B
EV/Sales
1.87
P/E ratio
16.01
FY Revenue
$21.27B
EPS
4.39
Gross Margin
39.53%
Div yield
0.20%
Sector
Healthcare
AI report sections
MIXED
GEHC
GE HealthCare Technologies Inc.
No AI report section text found yet for this symbol.
AI summarized at 10:47 AM ET, 2026-10-12
AI summary scores
INTRADAY:77SWING:55LONG:47
Volume vs average
Intraday (cumulative)
−12% (Below avg)
Vol/Avg: 0.88×
RSI
65.37(Strong)
Strong (60–70)
0255075100
MACD momentum
Intraday
+0.01 (Strong)
MACD: -0.02 Signal: -0.03
Short-Term
+0.68 (Strong)
MACD: 0.28 Signal: -0.40
Long-Term
+0.41 (Strong)
MACD: -0.08 Signal: -0.49
Intraday trend score
61.37
LOW61.37HIGH82.87
Latest news
GEHC•12 articles•Positive: 9Neutral: 2Negative: 1
NeutralZacks Investment Research• Na
Vaso Stock Surges 149% in a Year: What's Behind the Rally?
Vaso Corporation (VASO) has gained 149% over the past year, significantly outperforming its industry peers and the S&P 500. The healthcare-focused company reported improved Q2 2026 results with higher revenues and profitability, driven by growth in professional sales services and medical device segments. Following the divestiture of its IT services business, VASO is streamlining operations and strengthening its focus on healthcare. However, the company faces challenges including heavy dependence on GE HealthCare and ongoing profitability pressures in its proprietary medical products division.
While VASO's partnership with GEHC is a key revenue driver, the relationship represents a significant concentration risk. GEHC is mentioned as a critical business partner but no direct performance information is provided about GEHC itself.
NeutralZacks Investment Research• Na
ISRG Ahead of Q3 Earnings: Can Procedure Growth Sustain Momentum?
Intuitive Surgical (ISRG) is expected to report Q3 2026 earnings on October 20 with EPS projected at $2.61 (up 8.75%) and revenue growth of 15% to $2.88B. While the company benefits from international procedure growth and strong da Vinci 5 demand, it faces headwinds from moderating U.S. procedure growth, China pricing pressures, and higher costs. The stock trades at a premium valuation of 35.87X forward P/E, leaving limited room for disappointment.
Included as an industry peer with lower valuation (12.89X P/E F12M) and modest Q3 performance (2.1% gain), but no detailed analysis or outlook provided.
Digital X-ray Market - Global and Regional Analysis and Forecast, 2026-2036 | Mobile Imaging, AI Workflows, and Detector Innovation Drive Growth to $9.90 Billion
The global digital X-ray market is projected to grow from $5.79 billion in 2025 to $9.90 billion by 2036, expanding at a 5.09% CAGR. Growth is driven by the transition from analog to digital systems, adoption of mobile and retrofit solutions, AI-enabled workflows, and detector innovations. North America leads the market, while Asia-Pacific presents significant expansion opportunities. Key challenges include workforce shortages and integration complexity.
Listed as a prominent market participant with competitive offerings. Recent product launch (Definium Pace Select ET in July 2025) demonstrates active innovation and market presence in high-throughput, affordability-focused segments.
Global Mobile X-ray Systems Market Analysis and Forecast, 2026-2036 | AI-Enabled Digital Imaging and Asia-Pacific Growth Drive a $4.00 Billion Market by 2036
The global mobile X-ray systems market is projected to grow from $2.06 billion in 2025 to $4.00 billion by 2036, with a CAGR of 6.30%. Growth is driven by rising chronic disease prevalence, increasing hospitalization rates, and demand for point-of-care imaging. Digital systems dominate with 91.57% market share, while handheld/ultra-portable systems are the fastest-growing segment. Asia-Pacific leads regional growth at 7.43% CAGR, followed by North America and Europe.
Identified as a key player in the expanding mobile X-ray market with established diagnostic imaging capabilities, well-positioned to capture growth in North America (33.34% market share) and benefit from hospital replacement cycles.
Global Mobile C-Arm Market Analysis and Forecast, 2026-2036 | Market to Reach $3.71 Billion as Minimally Invasive Surgery, AI, and 3D Imaging Drive 5.35% CAGR
The global mobile C-arm market is projected to grow from $2.09 billion in 2025 to $3.71 billion by 2036, expanding at a 5.35% CAGR. Growth is driven by rising adoption of minimally invasive surgery, AI integration, 3D imaging, and aging populations. North America leads the market, with hospitals as the primary end-users. Key challenges include high capital costs and shortage of skilled professionals, while advanced storage and archiving capabilities present significant growth opportunities.
Company is actively innovating with recent product enhancements for its OEC 3D mobile CBCT C-arm to support procedural precision in interventional pulmonology (Nov 2024), demonstrating strong market engagement and technological advancement.
NegativeGlobeNewswire Inc.• The Law Offices Of Frank R. Cruz
Securities Fraud Investigation Into GE HealthCare Technologies Inc. (GEHC) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
The Law Offices of Frank R. Cruz is investigating GE HealthCare Technologies for potential federal securities law violations. The investigation follows the company's April 2026 earnings report, which revealed a PDx supplier recall that impacted profit performance and margins, leading to reduced full-year EPS guidance and a 13.2% stock price decline. The company's CFO also stepped down in July 2026.
The company faces a securities fraud investigation due to undisclosed supplier recall issues that impacted financial performance, reduced earnings guidance, caused a significant 13.2% stock price decline, and resulted in CFO departure, indicating serious operational and governance concerns.
PositiveZacks Investment Research• Na
GEHC vs. SYK: Which Stock Should Value Investors Buy Now?
In a comparison of two medical products stocks, GE HealthCare Technologies (GEHC) emerges as the more attractive option for value investors compared to Stryker (SYK). GEHC has a higher Zacks Rank (#2 Buy vs #3 Hold), lower forward P/E ratio (12.97 vs 18.23), and a lower P/B ratio (2.63 vs 4.36), earning a Value grade of B compared to SYK's C grade.
GEHC demonstrates stronger fundamentals for value investors with a higher Zacks Rank (#2 Buy), lower forward P/E ratio (12.97), lower P/B ratio (2.63), and a superior Value grade (B), indicating better earnings estimate revisions and more attractive valuation metrics.
PositiveZacks Investment Research• Na
GE HealthCare (GEHC) Upgraded to Buy: Here's Why
GE HealthCare Technologies (GEHC) received an upgrade to Zacks Rank #2 (Buy) based on upward trends in earnings estimates. The company is expected to earn $4.93 per share for fiscal year 2026, with analysts steadily raising estimates over the past three months. The upgrade positions GEHC in the top 20% of Zacks-covered stocks, suggesting potential for near-term stock price appreciation driven by improving business fundamentals.
Company received an upgrade to Zacks Rank #2 (Buy) based on upward earnings estimate revisions over the past three months. Positioned in the top 20% of Zacks-covered stocks, indicating superior earnings estimate revision features and potential for near-term stock price appreciation.
Software as a Medical Device Market Set for Rapid Growth Through 2034 as AI Innovation, Digital Health Adoption, and Regulatory Advances Reshape the Competitive Landscape
The global Software as a Medical Device (SaMD) market is projected to grow from USD 2.10 billion in 2025 to USD 8.90 billion by 2034, expanding at a CAGR of 17.4%. Growth is driven by AI-enabled diagnostics, digital therapeutics, cloud-based deployment, and maturing regulatory pathways. Diagnostic and screening software leads with 42% market share, while radiology applications dominate at 34%. North America holds 45% of the market, with Asia-Pacific expected to record the fastest growth.
PHGGEHCMDTHTFLSoftware as a Medical DeviceSaMDAI-enabled diagnosticsdigital therapeutics
Sentiment note
Listed among leading SaMD companies with strong portfolio in medical imaging and diagnostic software, positioned to benefit from market expansion and AI integration trends.
PositiveGlobeNewswire Inc.• Sns Insider
Ultrasound AI Market Size to Surge to USD 22.03 Billion by 2035 at a CAGR of 26.62% – SNS Insider
The global Ultrasound AI market is projected to grow from USD 2.09 billion in 2025 to USD 22.03 billion by 2035, with a CAGR of 26.62%. Growth is driven by deep learning advancements, point-of-care imaging adoption, and sonographer shortages. North America leads with 45.54% market share, while Asia-Pacific shows the fastest growth at 28.57% CAGR. Hardware dominates at 48% market share, with software as the fastest-growing segment.
Listed as a major key player in the rapidly growing ultrasound AI market with strong projected growth of 26.62% CAGR through 2035
PositiveZacks Investment Research• Na
GEHC or SYK: Which Is the Better Value Stock Right Now?
In a comparison of two Medical-Products sector stocks, GE HealthCare Technologies (GEHC) emerges as the superior value option for value investors. GEHC has a Zacks Rank of #2 (Buy) with improving earnings outlook, a lower forward P/E of 12.98 versus Stryker's 18.76, and a Value grade of A compared to Stryker's C grade. Key valuation metrics favor GEHC, including a lower PEG ratio (1.69 vs 1.76) and P/B ratio (2.63 vs 4.5).
GEHC demonstrates stronger value characteristics with a Zacks Rank #2 (Buy), improving earnings outlook, lower forward P/E ratio (12.98), superior Value grade (A), lower PEG ratio (1.69), and lower P/B ratio (2.63), making it the preferred choice for value investors.
PositiveGlobeNewswire Inc.• Sns Insider
Enterprise Imaging Solutions Market Set to Hit USD 6.69 Billion by 2035, Growing at a CAGR of 11.18% - SNS Insider
The Enterprise Imaging Solutions Market is projected to grow from USD 2.32 billion in 2025 to USD 6.69 billion by 2035, with a CAGR of 11.18%. Growth is driven by cloud-native platforms, AI-driven workflows, and vendor consolidation. North America leads with 44% market share, while Asia-Pacific shows the fastest growth at 15% CAGR. Software remains the largest component at 58% share, with cloud deployment and services as the fastest-growing segments.
Actively expanding market presence through strategic acquisitions (Intelerad Medical Systems, Ambra Health) in the high-growth enterprise imaging sector.
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal